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BACKGROUND: Mobile phone use is now ubiquitous, and scientific reviews have recommended research into its relation to leukaemia
risk, but no large studies have been conducted.
METHODS: In a case–control study in South East England to investigate the relation of acute and non-lymphocytic leukaemia risk to
mobile phone use, 806 cases with leukaemia incident 2003–2009 at ages 18–59 years (50% of those identified as eligible) and 585
non-blood relatives as controls (provided by 392 cases) were interviewed about mobile phone use and other potentially aetiological
variables.
RESULTS: No association was found between regular mobile phone use and risk of leukaemia (odds ratio (OR)¼1.06, 95% confidence
interval (CI)¼0.76, 1.46). Analyses of risk in relation to years since first use, lifetime years of use, cumulative number of calls and
cumulative hours of use produced no significantly raised risks, and there was no evidence of any trends. A non-significantly raised risk
was found in people who first used a phone 15 or more years ago (OR¼1.87, 95% CI¼0.96, 3.63). Separate analyses of analogue
and digital phone use and leukaemia subtype produced similar results to those overall.
CONCLUSION: This study suggests that use of mobile phones does not increase leukaemia risk, although the possibility of an effect after
long-term use, while biologically unlikely, remains open.
British Journal of Cancer (2010) 103, 1729–1735. doi:10.1038/sj.bjc.6605948 www.bjcancer.com
Published online 12 October 2010
& 2010 Cancer Research UK
Keywords: leukaemia; mobile phones; radiofrequency; epidemiology; case–control
                                               
Use of mobile phones has increased rapidly in recent years, leading
to public interest about possible carcinogenic effects. There is no
known biological mechanism by which radiofrequency (RF)
exposure from mobile phones could cause leukaemia or any other
cancer (Scientific Committee on Emerging and Newly Identified
Health Risks (SCENIHR), 2009); however, exposure is at least
anatomically relevant, as there is considerable bone marrow in the
skull and mandible (Ellis, 1961).
Expert groups have recommended that epidemiological studies
be conducted on the risks of brain tumours, acoustic neuromas,
salivary gland tumours and leukaemia (EC Expert Group, 1996;
Independent Expert Group on Mobile Phones (IEGMP), 2000). The
first three of these have been addressed by several studies, but have
not provided persuasive evidence of an association (International
Commission on Non-Ionizing Radiation Protection (ICNIRP),
2009; The INTERPHONE Study Group, 2010). Leukaemia is of
particular interest because it has a shorter induction period than
solid cancers after other exposures – risk increases 1–2 years after
exposure to ionising radiation or alkylating chemotherapy and
reaches a peak at 5–9 years, whereas solid tumour risk begins to
increase 5–10 years after exposure and remains raised for at least
25 years (van Leeuwen and Travis, 2005); an earlier effect of mobile
phone use on leukaemia risk than for solid tumours is, therefore,
plausible.
There have been few studies of mobile phone use and leukaemia
(Dreyer et al 1999; Schu ¨z et al, 2006; Kaufman et al, 2009), while
studies on leukaemia risk after RF exposure from other sources
have given inconsistent results (Ahlbom et al, 2004; Scientific
Committee on Emerging and Newly Identified Health Risks
(SCENIHR), 2009). We, therefore, conducted a case–control study
with over 800 cases in South East England to investigate leukaemia
risk in relation to mobile phone use.
MATERIALS AND METHODS
A case–control study was conducted in South East England
(London and the surrounding counties). Cases were defined as
people diagnosed with leukaemia (excluding chronic lymphocytic
leukaemia, as past evidence suggests that this has a different
aetiology from other subtypes (Boice, 2006)) at ages 18–59 years,
who were resident in the study region at diagnosis, and diagnosed
within a specified time period – namely 2003–2007 in most of the
region and 2003–2009 in two areas.
Cases were mainly ascertained via healthcare staff in haematol-
ogy and oncology units. Contact was made approximately weekly
so that potential cases could be identified rapidly, minimising
the number unable to participate because of illness or death.
Listings of leukaemia diagnoses were also obtained from the
Thames Cancer Registry at least every 6 months, and to ensure
completeness, extra cases identified from these listings were
included as potential cases, once the relevant hospital contact
had confirmed their eligibility. Potential cases who were hospital
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yin-patients were invited to participate in the study in person by
a research nurse, after clinical staff had confirmed that it
was appropriate to approach them. Potential cases who were at
home were invited to participate by letter, and later contacted
by telephone by a research nurse if they did not reply. The
information provided to potential participants presented the study
as an investigation of the relation of features of modern lifestyle
to the causation of leukaemia; it did not specify mobile phone use
as the main exposure of interest, mentioning this only as one of the
several subjects that would be covered.
Controls were non-blood relatives of the cases (or equivalent for
non-married couples), who had never been diagnosed with
leukaemia, did not live with the case and fitted the same age and
residence criteria as the cases. This control source was used
because it has become increasingly difficult to obtain high
response rates for population-based controls (Morton et al,
2006). It was hoped that people with a relative with leukaemia
would be more motivated to participate in the study, and that this
would result in higher response rates. Cases were asked to provide
details of all non-blood relatives, and those who met the inclusion
criteria and who the case was willing for us to approach were
invited to participate by letter, which was followed up by phone by
a research nurse, if they did not reply.
No information on mobile phone use of non-participants was
collected from healthcare staff or relatives, as ethics permission
was not obtained for this.
Participants were interviewed face-to-face by a research nurse in
hospital, at home or at another convenient place and signed
informed consent was obtained. Medical research ethics approval
was granted by the South East Multi-centre Research Ethics
Committee. Participants were asked about demographic factors
and exposure to a range of known and potential risk factors for
leukaemia, including RF exposure, with a particular focus on
mobile phone use. The phone section of the questionnaire was
based on that used in the Interphone study (Cardis et al, 2007),
with some modifications. Subjects were asked whether they had
ever used a mobile phone regularly, which was defined as at
least 6 months making or receiving at least one call a week on
average. They were asked which makes and models they had used
and to specify, for each phone, the year that they started and
stopped using the phone, their average number of calls per day or
per week, the average length of the calls, the phone network used
and the proportion of use that was hands free. If participants were
unable to provide an average call frequency or duration, they were
asked to give a range. Data on use of cordless phones were not
collected, as the power output from these is much lower than that
from mobile phones – around 10% of the typical output from a
digital mobile phone and 1% of that from an analogue phone
(Advisory Group on Non-Ionising Radiation (AGNIR), 2003;
Hardell et al, 2006b).
Statistical analysis
Analyses were conducted for leukaemia overall, and separately for
acute myeloid leukaemia (AML), acute lymphoblastic leukaemia
(ALL) and chronic myeloid leukaemia (CML). All controls were
used in all analyses. Exposures were evaluated up to the diagnosis
date for cases, and an equivalent date before the interview for
controls, referred to as the ‘reference date’, so that phone use in
controls was not overestimated because of rapidly increasing use
in the general population during the study period and controls
being interviewed later than cases, and so that similarly distant
time periods were recalled by cases and controls. As controls were
not individually matched to cases, the reference dates for controls
were constructed by stratifying cases by half-year interview period
and whole-year interview lag time, and randomly allocating
controls in each half-year interview period to lag time strata in
the same proportions as the cases, so that the distributions of cases
and controls over the lag time strata were similar. The mean lag time
for cases in each stratum was subtracted from the interview date for
each control in the same stratum to create their reference date.
The phone use histories provided by participants were used to
calculate number of years since first use of a mobile phone, total
lifetime years of use and total cumulative number of calls and
hours of use. Adjusted versions of these variables were calculated
taking into account the extent of hands-free use, by multiplying the
average call length for each phone by the proportion of time that
the phone was not used hands free. Participants’ cumulative
number of calls or hours of use were categorised as unknown if the
extent of usage of at least one phone was unknown. As this meant
that participants who had used more phones might be more likely
to be in the unknown category, however, we also re-analysed the
data after imputing missing phone usage values by using data from
the previous or next mobile phone the participant used, where this
information was available. Where a participant gave a range for
their average call frequency or duration, the mean of the upper and
lower bounds was used in calculations. These analyses were
repeated, however, using a number of different methods of
imputing the value from a range, to assess whether our choice of
method had influenced the results. In these alternative methods,
the value was imputed as the lower bound, the upper bound and
weighted means giving more weight to the lower, or upper, bound.
Analyses were also repeated classifying the value as unknown
where a range was given.
Risks of leukaemia in relation to aspects of phone use were
estimated by calculating odds ratios (OR) and 95% confidence
intervals (CI), using unconditional logistic regression adjusted for
5-year age group at reference date, sex, socio-economic status
(classified using the residentially based ACORN score (CACI,
2009)), area of residence (London or surrounding area), ethnicity
(white, non-white or mixed or unknown), smoking status at
reference date (current smoker, ex-smoker, never smoker or
unknown) and interview lag time and half-year period stratum.
Analyses were also repeated using conditional logistic regression,
with strata of age, sex and area of residence and adjusted for socio-
economic status, ethnicity, smoking status and interview lag time
and half-year period stratum. Trend tests were conducted for
ordinal variables, using a likelihood-ratio test comparing a model
excluding the variable of interest with a model containing the
variable, as a categorical variable with each category’s value being
the mean of the values in that category.
The above analyses were repeated for analogue and digital
phone use separately and by sex. We also re-analysed the data
excluding participants who had been exposed to leukemogenic
chemotherapy, radiotherapy or chloramphenicol, or who had a
cytogenetic abnormality predisposing to leukaemia, adjusting for
reported use of other communication devices and occupational
exposure to radar, telecommunication antennae and masts, and
excluding participants who reported implausibly high levels of
phone use. Analyses were conducted using the statistical package
Stata (Stata Corporation, 2007).
RESULTS
We identified 1660 potentially eligible leukaemia cases, of whom
380 had died; 52 were too ill or otherwise medically unsuitable to
be interviewed; for 54 cases, we could not gain consultant
permission; for 33 cases, ascertained via the cancer registry, the
hospital concerned had no record of the patient attending for
leukaemia; 47 cases were not approached for other reasons; 176
cases replied to the invitation letter to say that they were not
willing to participate; 112 cases never replied and could not be
contacted by phone and 806 cases were interviewed. The cases who
took part comprised 50% of the eligible leukaemia cases identified
(excluding the 33 patients who were not recorded as leukaemia
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ypatients at the relevant hospitals), and 82% of those who were sent
an invitation to take part and are known to have received it.
Participation rates were similar for males (49%) and females
(50%); diminished with lower socio-economic status (62% in the
highest group, 34% in the lowest) and diminished with calendar
year (54% in 2003, 44% in 2008/2009). The interviewed cases
comprised 449 with AML, 125 with ALL, 154 with CML, 55 with
hairy cell leukaemia, 7 with acute monocytic leukaemia and 16
other types or of mixed phenotype (Table 1).
Of the interviewed cases, 57% provided details of eligible
relatives, 28% had no suitable relatives and 15% were not willing to
provide details of relatives. In total, 781 potential controls were
identified and invited to take part, of whom 589 (75%) were
interviewed (4 were aged over 59 years at reference date, and were,
therefore, excluded from analysis). This comprised 75% of all
those who sent an invitation to take part, and 86% of those who
were known to have received the invitation letter. The participa-
tion rate was slightly higher in females (77%) than males (73%),
diminished with decreasing socio-economic status (80% in the
highest group, 71% in the lowest), and decreased with calendar
year (81% in 2003, 66% in 2008/2009) and younger age (490% at
ages 450 years, 60% at ages o25 years). The interviewed controls
were provided by 392 different cases, and comprised 203 sisters-in-
law (or equivalent for non-married couples), 175 brothers-in-law
(or equivalent), 50 sons-in-law (or equivalent), 43 daughters-in-
law (or equivalent) and 118 other non-blood relatives.
Regular phone users had a similar risk of leukaemia to never
regular users (OR¼1.06, 95% CI¼0.76, 1.46; Table 2). There was
no significant trend of risk in relation to years since first use or
total years of use, although the risk was non-significantly raised in
the longest categories (OR¼1.87, 95% CI¼0.96, 3.63 and
OR¼1.63, 95% CI¼0.81, 3.28, respectively).
Risk was not related to cumulative number of calls or hours of
use. The results were similar when analyses were repeated using
different methods of imputing average frequency or length of calls
from a range (not in table). Repetition of the above analyses
separately by digital or analogue phone use (Table 3) and by sex
(not in table) gave similar results.
In analyses by cytological subtype (Table 4), there was no
significant variation in results by type, and no significant trend in
risk with years since first use, years of use or cumulative hours of
use. The only significant result was a reduced risk of ALL 10–14
years after first use (OR¼0.37, 95% CI¼0.14, 0.94). There was a
borderline significantly raised risk of AML X15 years after first
use (OR¼2.08, 95% CI¼0.98, 4.39) and of ALL after 10–14 years
of use (OR¼0.39, 95% CI¼0.15, 1.00). The results were unchanged
when the 36 cases and 9 controls who had been exposed to
leukemogenic chemotherapy, radiotherapy or chloramphenicol or
who had a cytogenetic abnormality predisposing to leukaemia
Table 1 Leukaemia cases and controls: descriptive characteristics
Cases Controls
Characteristic No. % No. %
Sex
Male 454 56.3 259 44.3
Female 352 43.7 326 55.7
Age at diagnosis (years)
a
o25 65 8.1 29 5.0
25–34 118 14.6 153 26.2
35–44 218 27.0 164 28.0
45–54 251 31.1 174 29.7
55–59 154 19.1 65 11.1
Socio-economic status (ACORN score)
b
1–12 198 24.6 136 23.3
13–23 211 26.2 111 19.0
III 209 25.9 183 31.3
IV 96 11.9 85 14.5
V 92 11.4 69 11.8
Place of residence
London 445 55.2 283 48.4
Outside London 361 44.8 302 51.6
Ethnicity
White 698 86.6 544 93.0
Non-white 100 12.4 32 5.5
Mixed and unknown 8 1.0 9 1.5
Diagnosis
AML 449 55.7
ALL 125 15.5
CML 154 19.1
HCL 55 6.8
Other and unspecified 23 2.9
Total 806 100.0 585 100.0
Abbreviations: AML¼acute myeloid leukaemia; ALL¼acute lymphoblastic leukaemia;
CML¼chronic myeloid leukaemia; HCL¼hairy cell leukaemia.
aFor controls, age at
reference date – see Materials and methods.
bOne missing value for socio-economic
status, controls.
Table 2 Risks of leukaemia in relation to use of mobile phones
Cases
no.
Controls
no.
Odds
ratio
a 95% CI
Ever use
b
Never or non-regular use 132 99 1.00
Regular use 674 486 1.06 0.76, 1.46
Years since first use
Never or non-regular use 132 99 1.00
0.5–4
c 195 146 0.98 0.68, 1.42
5–9 307 229 1.07 0.75, 1.53
10–14 111 89 0.98 0.63, 1.51
X15 50 16 1.87 0.96, 3.63
Unknown 11 6 1.08 0.35, 3.39
P-trend 0.27
Lifetime years of use
Never or non-regular use 132 99 1.00
0.5–4
c 201 153 0.97 0.67, 1.39
5–9 309 228 1.10 0.77, 1.58
10–14 110 84 1.04 0.67, 1.61
X15 42 15 1.63 0.81, 3.28
Unknown 12 6 1.17 0.38, 3.61
P-trend 0.30
Cumulative no. of calls
Never or non-regular use 132 99 1.00
oMedian (o5350) 292 228 1.01 0.71, 1.42
Median-third quartile
(5350–16062)
166 115 1.13 0.76, 1.69
4Third quartile (416062) 160 113 1.03 0.68, 1.56
Unknown 56 30 1.37 0.78, 2.43
P-trend 0.99
Cumulative hours of use
Never or non-regular use 132 99 1.00
oMedian (o284) 283 226 0.97 0.69, 1.36
Median-third quartile
(284–1156)
160 115 1.14 0.76, 1.71
4Third quartile (41156) 176 114 1.19 0.79, 1.80
Unknown 55 31 1.30 0.74, 2.29
P-trend 0.31
Abbreviation: CI¼confidence interval.
aAdjusted for age, sex, socio-economic status,
area of residence, ethnicity, smoking status and interview lag time and period.
bAt
least one call a week on average for at least 6 months.
cLower limit 0.5 years due to
definition of regular use.
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other RF exposure through use of other communication devices or
occupational exposure, did not materially alter the results, and
similar results were obtained using conditional logistic regression
(not in table). In analyses based on means where ranges were given,
26 (3.2%) cases and 17 (2.8%) controls were allocated values
of average daily use of a particular phone of over 6h by the
calculations, and 83 (10.3%) cases and 53 (8.8%) controls were
allocated values of over 2h. Re-analysing the data after excluding
participants with a calculated usage of over 2h per day, as well as
those who reported first using a mobile phone before 1985, when
the first mobile phone networks became available in Britain
(4 cases, 2 controls), produced similar results to those in Table 2
(not in table). Repeating the analysis restricted to the highest socio-
economic status category, in which the response rate was highest,
produced no significant results, and no evidence of any raised risks
(not in table).
DISCUSSION
There are currently 44.6 billion mobile phone subscriptions in
use worldwide (International Telecommunication Union (ITU),
2010), and thus any potential health effects could be of great public
health importance. Although no biological mechanism has been
identified, there is considerable public and scientific interest in the
possibility that RF exposure from phone use might affect cancer
risk (Scientific Committee on Emerging and Newly Identified
Health Risks (SCENIHR), 2009). Leukaemia risk is of interest
because of the proximity of phone use to the skull and mandible,
which contain 13% of the body’s active bone marrow (Ellis, 1961).
We found no association between regular phone use and
developing leukaemia, and no significant results relating to time
since first use, total years of use or cumulative number of calls or
hours of use, although there was a non-significantly 1.9-fold raised
risk in people who had first used a mobile phone 15 or more years
before the reference date.
The results from the few previous studies are largely consistent
with ours. Two cohort studies based on subscription data, and
hence without direct information on who used the phone, one in
Denmark with 351 leukaemia cases (Schu ¨z et al, 2006) and one in
the United States with 15 deaths from leukaemia (Dreyer et al,
1999), found no raised risk in phone subscribers. A case–control
study of 180 cases in Thailand (Kaufman et al, 2009), among
participants with a low prevalence of phone use, found a slight non-
significantly raised risk in people who had ever used a mobile
phone. There are no previous data on risk after 15 years of use, but
the Danish cohort, in which the longest subscription category was
10 or more years, found no substantially raised risk and no evidence
of a trend. It seems unlikely that the raised risk in our study
represents a true effect, as leukaemia is associated with particularly
short induction periods for known carcinogens, for example
ionising radiation and alkylating chemotherapy (van Leeuwen and
Travis, 2005) – whereas there was no evidence of a raised risk at
shorter times since first use in our data or the Danish cohort.
For both cumulative number of calls and hours of use, the
highest risk was found in the unknown category. As people became
more likely to be in this category the more phones they had used,
this could suggest that more cases than controls had used a large
number of phones. However, a re-analysis of these variables
imputing missing phone usage information, where possible,
produced similar results, suggesting that this is not the reason,
and that cases simply found it harder than controls to recall details
of their phone use. As participants often gave a range when
Table 3 Risks of leukaemia in relation to various characteristics of analogue or digital phone use
Type of phone
Analogue Digital
Factor Cases no. Controls no. OR 95% CI Cases no. Controls no. OR 95% CI
Ever use
Never or non-regular phone use 132 99 1.00 132 99 1.00
Regular use of specified type of phone 129 100 1.18 0.75, 1.86 644 476 1.03 0.75, 1.43
Unknown 111 57 1.40 0.85, 2.30 30 10 2.25 0.99, 5.01
Years since first use
Never or non-regular phone use 132 99 1.00 132 99 1.00
0.5–4 1 0 214 157 1.03 0.71, 1.48
5–9 47 51 0.85 0.48, 1.49 285 221 1.02 0.71, 1.47
X10 80 47 1.54 0.91, 2.62 46 40 0.78 0.44, 1.38
Unknown 112 59 1.40 0.85, 2.30 129 68 1.35 0.87, 2.08
P-trend 0.08 0.65
Lifetime years of use
Never or non-regular phone use 132 99 1.00 132 99 1.00
0.5–4 72 63 1.08 0.64, 1.80 216 162 1.00 0.70, 1.44
5–9 33 23 1.19 0.60, 2.35 285 214 1.06 0.74, 1.53
X10 3 1 5.30 0.30, 94.18 39 38 0.67 0.37, 1.23
Unknown 132 70 1.40 0.88, 2.24 134 72 1.33 0.87, 2.05
P-trend 0.25 0.60
Cumulative hours of use
a
Never or non-regular phone use 132 99 1.00 132 99 1.00
oMedian 43 42 0.94 0.53, 1.68 260 207 0.98 0.69, 1.38
Median-third quartile 31 24 1.16 0.59, 2.28 133 102 1.05 0.69, 1.59
4Third quartile 32 21 1.42 0.69, 2.93 132 96 1.05 0.68, 1.62
Unknown 134 70 1.45 0.91, 2.32 149 81 1.33 0.87, 2.02
P-trend 0.14 0.63
Abbreviations: OR¼odds ratio; CI¼confidence interval.
aAnalogue: median¼129, third quartile¼667; digital: median¼251, third quartile¼1079.
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no obviously correct method here, we repeated the analysis several
times using different methods. We also repeated analyses
excluding participants who reported implausible phone usage
patterns or dates. The results from these analyses were similar to
those in Table 2.
The three main leukaemia subtypes share some risk factors,
for example ionising radiation (Preston et al, 1994), but other
exposures have different effects on different subtypes, for example
smoking (Doll, 1996). We, therefore, analysed the effect of phone
use on each subtype separately. The only previous such analysis
was based on o20 ever users per subtype and found no significant
results (Kaufman et al, 2009). Our analyses produced similar
results to the combined analyses; the only significant result was a
reduced risk of ALL in the 10–14 years since first use category,
with a near-significant reduced risk in the corresponding category
of lifetime years of use; however, these were based on small
numbers, and there was no evidence of a trend in either variable.
We also found a near-significant raised risk of AML in the highest
category of years since first use, but no trend and as discussed
above, AML tends to have a short latency period following other
risk factors, so this is unlikely to represent a true effect. As we
conducted a large number of comparisons in this analysis, one
might expect some significantly reduced or raised risks to occur by
chance alone.
If phone use had a leukemogenic effect, one might expect this to
be greatest in relation to use of analogue phones, as these have a
higher average power output than digital phones (Ahlbom et al,
2004). However, we saw neither raised risk in regular users of
either type, nor any association between risk and years since first
use, total years of use or total hours of use of either type.
As the analyses in this study are based on self-reported data, and
participants’ first mobile phone use was often many years before
their interview (15 years or more for 81 participants), it seems
likely that inaccuracies in recall will have led to a substantial
amount of misclassification. Investigations into the validity of
phone use data within the Interphone study (Cardis et al, 2007),
for which phone use histories were collected in a similar way to
ours, found substantial random error and some systematic error in
reported mobile phone use, with participants tending to under-
estimate number of calls and overestimate length of calls (Vrijheid
et al, 2006). If there were non-differential misclassification, this
would be expected to bias results towards the null. A possible
increase in overestimation of phone use in more distant time
periods by cases was also found in Interphone (Vrijheid et al,
2009a), which could potentially explain the slightly raised risk we
found in the highest category of cumulative hours of phone use
(Table 2).
Population-based control participation rates have been declin-
ing in recent years (Morton et al, 2006). We, therefore, used a
different control source in this study, non-blood relatives of cases,
and achieved a good participation rate (75%). A disadvantage of
this control source is potential overmatching, but this would give a
risk of loss of statistical efficiency rather than bias (Rothman and
Greenland, 1998). On the other hand, the risk of selection bias was
reduced by the high participation rate. This may be why we did not
find, as in many population-based case–control studies of brain
tumour risk in phone users, an apparently reduced risk in users
(Schoemaker et al, 2005; Lo ¨nn et al, 2006; Lahkola et al, 2007; The
INTERPHONE Study Group, 2010), which has been ascribed to
potential controls being less likely to participate if they were not
regular users (Lahkola et al, 2005; Vrijheid et al, 2009b). A second
Table 4 Risks of acute myeloid leukaemia, acute lymphoblastic leukaemia and chronic myeloid leukaemia in relation to mobile phone use
Leukaemia subtype
a
AML ALL CML
Factor Cases no. OR 95% CI Cases no. OR 95% CI Cases no. OR 95% CI
Ever use
Never or non-regular use 73 1.00 18 1.00 25 1.00
Regular use 376 1.07 0.73, 1.57 107 0.59 0.31, 1.13 129 1.48 0.85, 2.59
Years since first use
Never or non-regular use 73 1.00 18 1.00 25 1.00
0.5–4 109 1.02 0.66, 1.58 29 0.51 0.24, 1.11 40 1.36 0.72, 2.57
5–9 171 1.08 0.71, 1.65 56 0.64 0.32, 1.30 56 1.56 0.84, 2.90
10–14 58 0.91 0.54, 1.54 12 0.37 0.14, 0.94 28 1.99 0.94, 4.22
X15 31 2.08 0.98, 4.39 8 1.41 0.45, 4.37 4 1.25 0.34, 4.65
Unknown 7 0.92 0.26, 3.20 2 0.90 0.12, 6.87 1 0.49 0.02, 9.82
P-trend 0.32 0.46 0.34
Lifetime years of use
Never or non-regular use 73 1.00 18 1.00 25 1.00
0.5–4 113 1.00 0.65, 1.54 30 0.51 0.23, 1.09 40 1.29 0.68, 2.43
5–9 172 1.11 0.73, 1.70 56 0.66 0.33, 1.34 58 1.66 0.89, 3.09
10–14 57 0.98 0.58, 1.65 12 0.39 0.15, 1.00 27 1.97 0.93, 4.21
X15 26 1.76 0.81, 3.81 7 1.17 0.36, 3.78 3 1.06 0.25, 4.52
Unknown 8 1.05 0.31, 3.53 2 0.88 0.11, 6.76 1 0.49 0.02, 9.93
P-trend 0.39 0.56 0.30
Cumulative hours of use
Never or non-regular use 73 1.00 18 1.00 25 1.00
oMedian 152 0.96 0.64, 1.44 42 0.61 0.30, 1.22 62 1.48 0.82, 2.67
Median-third quartile 92 1.26 0.78, 2.04 25 0.52 0.23, 1.15 32 1.70 0.85, 3.40
4Third quartile 99 1.23 0.76, 2.01 31 0.59 0.27, 1.31 28 1.51 0.72, 3.14
Unknown 33 1.22 0.64, 2.34 9 0.73 0.25, 2.15 7 0.87 0.28, 2.75
P-trend 0.48 0.92 0.90
Abbreviations: AML¼acute myeloid leukaemia; ALL¼acute lymphoblastic leukaemia; CML¼chronic myeloid leukaemia; OR¼odds ratio; CI¼confidence interval.
aControl
numbers as shown in Table 2.
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respect is that our recruitment literature described a study of
leukaemia and modern life, not specifically of phone use.
Our participation rate among cases identified as eligible was
50%. The main reason for non-participation was not unwillingness
to take part, but rather that cases were too ill, or died soon after
diagnosis. We made efforts to reduce non-response by using a
rapid case ascertainment system, and making follow-up telephone
calls to potential participants who did not reply to the invitation
letter, which resulted in a participation rate of 82% among those
known to have received the invitation to take part, but given the
rapid clinical deterioration in many patients, some non-participa-
tion was inevitable. If any leukaemias induced by phone use were
particularly aggressive, then non-participation because of illness or
death could in principle result in any true leukaemogenic effect
being underestimated. A number of patients (all 36 CML patients
at one hospital) also had to be excluded because they were under
the care of a clinician who refused access to her patients; however,
this seems unlikely to have caused bias. To investigate the effect of
the participation rate, the analysis was repeated, restricted to the
highest socio-economic category, in which the response rate was
highest, but no evidence of a raised risk was found.
Previous epidemiological studies of the carcinogenicity of
mobile phone use have mainly focused on brain tumours, but
only those from one group have suggested raised risk in users
(Hardell et al, 2006a); literature overall suggests no causal
association (International Commission on Non-Ionizing Radiation
Protection (ICNIRP), 2009). Furthermore, biological studies have
found no persuasive evidence of any mechanism by which RF
could cause cancers (Scientific Committee on Emerging and Newly
Identified Health Risks (SCENIHR), 2009).
In conclusion, our results do not suggest that use of mobile
phones increases risk of leukaemia overall, or of any subtype.
However, the possibility of an effect after long-term use, although
biologically unlikely, is left open, and future results from existing
cohorts (and from case–control studies, if any are conducted)
would be of interest.
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